Estriol
Estriol is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against estrogen receptor. In addition, it is known to target estrogen receptor beta.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 3.6oz biest 2.5 estrogen cream | unapproved drug other | 2025-06-01 |
| advanced formula estro-life | unapproved drug other | 2022-03-31 |
| arthcal estriol face cream for women | C200263 | 2025-02-28 |
| balance plus cream | unapproved drug other | 2025-06-01 |
| biest 2.5 estrogen cream | unapproved drug other | 2021-06-21 |
| biest 2.5 estrogen cream (lavender scented) | unapproved drug other | 2021-06-21 |
| biest 5.0 estrogen cream | unapproved drug other | 2025-06-01 |
| biest 5.0 estrogen cream - 3.6oz | unapproved drug other | 2025-06-01 |
| estriol 5.0 cream | unapproved drug other | 2025-06-01 |
| estriol cream | C200263 | 2025-07-28 |
Show 4 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G03: Sex hormones and modulators of the genital system
— G03C: Estrogens, sex hormones and modulators of the genital system
— G03CA: Natural and semisynthetic estrogens, plain
— G03CA04: Estriol
— G03CC: Estrogens, combinations with other drugs
— G03CC06: Estriol
HCPCS
No data
Clinical
Clinical Trials
47 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrophic vaginitis | D059268 | EFO_1001271 | — | 2 | 4 | 4 | 3 | 5 | 18 |
| Atrophy | D001284 | — | — | 2 | 4 | 3 | 2 | 6 | 17 |
| Syndrome | D013577 | — | — | — | 2 | — | 2 | 4 | 8 |
| Vaginitis | D014627 | EFO_0005757 | N76 | 2 | — | 1 | 1 | 1 | 5 |
| Prolapse | D011391 | — | — | — | — | 1 | 2 | 1 | 4 |
| Pelvic organ prolapse | D056887 | EFO_0004710 | — | — | — | 1 | 2 | — | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | 1 | 1 | 2 |
| Endometrial hyperplasia | D004714 | — | N85.0 | — | — | — | 1 | — | 1 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | — | — | 1 | — | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Menopause | D008593 | EFO_0003922 | N95 | 2 | 2 | 1 | — | — | 5 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 3 | 1 | — | — | 3 |
| Sclerosis | D012598 | — | — | — | 3 | 1 | — | — | 3 |
| Neurogenic urinary bladder | D001750 | HP_0000011 | N31 | — | 1 | 1 | — | — | 1 |
| Pelvic floor disorders | D059952 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Premenstrual syndrome | D011293 | — | N94.3 | — | 2 | — | — | — | 2 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 2 | — | — | — | 2 |
| Hereditary hemorrhagic telangiectasia | D013683 | — | I78.0 | — | 1 | — | — | — | 1 |
| Epistaxis | D004844 | EFO_0003895 | R04.0 | — | 1 | — | — | — | 1 |
| Telangiectasis | D013684 | — | — | — | 1 | — | — | — | 1 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 1 | — | — | — | 1 |
| Habitual abortion | D000026 | EFO_1000954 | N96 | — | 1 | — | — | — | 1 |
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dyspareunia | D004414 | — | N94.1 | 1 | — | — | — | 1 | 2 |
| Physiological sexual dysfunction | D012735 | — | — | 1 | — | — | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | — | — | 3 | 3 |
| Postmenopause | D017698 | — | — | — | — | — | — | 3 | 3 |
| Vulvodynia | D056650 | — | N94.81 | — | — | — | — | 2 | 2 |
| Vulvar vestibulitis | D054515 | — | N94.810 | — | — | — | — | 2 | 2 |
| Kallmann syndrome | D017436 | Orphanet_478 | E23.0 | — | — | — | — | 1 | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | — | — | — | 1 | 1 |
| Chromosome aberrations | D002869 | Orphanet_68335 | — | — | — | — | — | 1 | 1 |
| Chromosome disorders | D025063 | EFO_0003831 | Q99.9 | — | — | — | — | 1 | 1 |
| Female urogenital diseases | D052776 | — | — | — | — | — | — | 1 | 1 |
| Urogenital diseases | D000091642 | — | — | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Estriol |
| INN | _ |
| Description | Estriol is a 3-hydroxy steroid that is estra-1,3,5(10)-trien-3-ol substituted by additional hydroxy groups at positions 16 and 17 (16alpha,17beta-stereoisomer). It has a role as an estrogen, a human metabolite, a human xenobiotic metabolite and a mouse metabolite. It is a 3-hydroxy steroid, a 16alpha-hydroxy steroid and a 17beta-hydroxy steroid. It derives from a hydride of an estrane. |
| Classification | Small molecule |
| Drug class | estrogens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O |
Identifiers
| PDB | — |
| CAS-ID | 50-27-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL193482 |
| ChEBI ID | 27974 |
| PubChem CID | 5756 |
| DrugBank | DB04573 |
| UNII ID | FQ5FV85BS0 (ChemIDplus, GSRS) |
Target
Agency Approved
ESR1
ESR1
Organism
Homo sapiens
Gene name
ESR1
Gene synonyms
ESR, NR3A1
NCBI Gene ID
Protein name
estrogen receptor
Protein synonyms
E2 receptor alpha, ER-alpha, Estradiol receptor, estrogen nuclear receptor alpha, estrogen receptor alpha E1-E2-1-2, estrogen receptor alpha E1-N2-E2-1-2, Nuclear receptor subfamily 3 group A member 1, oestrogen receptor alpha
Uniprot ID
Mouse ortholog
Esr1 (13982)
estrogen receptor (Q9QY52)
Alternate
ESR2
ESR2
Organism
Homo sapiens
Gene name
ESR2
Gene synonyms
ESTRB, NR3A2
NCBI Gene ID
Protein name
estrogen receptor beta
Protein synonyms
estrogen receptor beta 2, estrogen receptor beta 4, Nuclear receptor subfamily 3 group A member 2, oestrogen receptor beta
Uniprot ID
Mouse ortholog
Esr2 (13983)
estrogen receptor beta (Q91Z86)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Estriol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,659 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
227 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use